Navigation Links
DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
Date:11/25/2008

PARSIPPANY, N.J. and LEIDEN, Netherlands, Nov. 25 /PRNewswire/ -- DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX), today announced that Hungary-based Gedeon Richter Plc. signed a commercial license agreement allowing Gedeon Richter to develop and produce certain biopharmaceuticals on the PER.C6(R) platform.

Other terms of the agreement were not disclosed.

About PER.C6(R) technology

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

About XD(TM) technology

DSM's XD(TM) technology has been developed as a proprietary system to drive yield improvements in mammalian systems. "XD" stands for extreme density, as the process is able to push the cell density within the bioreactor to maximum productivity.

About Crucell

Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6(R) production technology. The Company licenses its PER.C6(R) technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over 1000 people. For more information, please visit http://www.crucell.com.

About DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6(R) human cell line as a production platform for recombinant proteins and monoclonal antibodies. The combination of the PER.C6(R) human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market.

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: http://www.dsm.com.

DSM Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and Crucell and information currently available to both companies. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM and Crucell do not guarantee that their expectations will be realized. Furthermore, DSM and Crucell have no obligation to update the statements contained in this press release.

Crucell N.V. has identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to the Form 20-F, as filed by Crucell N.V. with the U.S. Securities and Exchange Commission on May 7, 2008, and in particular the section entitled "Risk Factors". Crucell N.V. prepares its financial statements under International Financial Reporting Standards (IFRS).

    For further information please contact:

    DSM Pharmaceutical Products   Crucell N.V.
    Karen King                    Oya Yavuz
    President                     Director Corporate Communications &
    DSM Biologics                 Investor Relations
    Tel: +1-973-257-8427          Tel: +31-71-519 7064
    karen.king@dsm.com            ir@crucell.com

    DSM Biologics
    Marcel Lubben
    Vice President
    Marketing, Sales & NBD
    Tel: +31-46-477 3343
    marcel-m.lubben@dsm.com

'/>"/>
SOURCE DSM Pharmaceutical Products
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
2. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
7. MedImmune Submits Biologics License Application to FDA for Motavizumab
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 31, 2015. --> --> ... loss of $29.3 million, or $0.34 loss per share, compared to ... for the same period in 2014. For the year ended December ... or $1.05 loss per share, as compared to a net loss ...
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016  Bioethics International, ... how medicines are researched, developed, marketed and made accessible to ... BMJ Open had named the publication of the ... for 2015. The publication is also featured as one of ... published in the last year that are most frequently read. ...
(Date:2/11/2016)... NY (PRWEB) , ... February ... ... a business-to-business publication dedicated to delivering cutting-edge information focused on the development ... Life Sciences to become a premier sponsor of the 2016 BioProcess International ...
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
Breaking Biology Technology:
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market ... iris recognition is more widely accepted for ... with both fingerprint and iris recognition technology ... user to avoid purchasing two individual biometrics ...
(Date:2/8/2016)... 2016 Worldcore is ... innovation for clients, comfort and unbeatable security, with ... --> Worldcore is the first EU-regulated ... comfort and unbeatable security, with a Voice Biometrics ... Worldcore is the first EU-regulated global payment ...
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
Breaking Biology News(10 mins):